This communication contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of forward-looking words or phrases such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “opportunity,” “plan,” “predict,” “project,” “potential,” “estimate,” “should,” “will,” “would” or the negative of these terms or other words of similar meaning. These statements are subject to known and unknown risks, uncertainties and assumptions, and if any such risks or uncertainties materialize or if any of the assumptions prove incorrect, our actual results could differ materially from those expressed or implied by such statements. Factors that may cause actual results to differ materially from those contemplated by such forward-looking statements include, but are not limited to: risks related to the development of Veru Inc.’s (the “Company”) product portfolio, including risks regarding the regulatory pathway to secure FDA or other regulatory approval of the Company’s drug candidates, the anticipated timeframe for FDA submissions and approvals, costs for clinical studies and regulatory submissions, clinical study results, including potential benefits and absence of adverse events, and the depth of the Company’s drug pipeline, the market potential for the Company’s drug candidates; potential delays in the timing of and results from clinical trials and studies, including potential delays in the recruitment of patients and their ability to effectively participate in such trials and studies due to COVID-19, and the risk that such results will not support marketing approval and commercialization; potential delays in the timing of any submission to the FDA and regulatory approval of products under development and the risk that disruptions at the FDA caused by the COVID-19 pandemic may delay the review of submissions or approvals for new drugs; clinical results or early data from clinical trials may not be replicated or continue to occur in additional trials or may not otherwise support further development in the specified drug candidate or at all; our pursuit of a COVID-19 treatment candidate is at an early stage and we may be unable to develop a drug that successfully treats the virus in a timely manner, if at all; risks related to our commitment of financial resources and personnel to the development of a COVID-19 treatment which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties about the longevity and extent of COVID-19 as a global health concern and the possibility that as vaccines become widely distributed the need for new COVID-19 treatment candidates may be reduced or eliminated; government entities may take actions that directly or indirectly have the effect of limiting opportunities for VERU-111 as a COVID-19 treatment, including favoring other treatment alternatives or imposing price controls on COVID-19 treatments; the risk in obtaining any regulatory approval and the products being commercially successful; risks relating to the ability of the Company to obtain sufficient financing on acceptable terms when needed to fund development and Company operations; product demand and market acceptance; competition in the Company’s markets and therapeutic areas and the risk of new or existing competitors with greater resources and capabilities and new competitive product introductions; the risk in sales being affected by regulatory developments, including a reclassification of the products or repeal of the Patient Protection and Affordable Care Act; price erosion, both from competing products and increased government pricing pressures; manufacturing and quality control problems; compliance and regulatory matters including costs and delays resulting from the extensive governmental regulation, and effects of healthcare insurance and regulation, including reductions in reimbursement and coverage or reclassification of products; some of the Company’s products are in development and the Company may fail to successfully commercialize such products; risks related to intellectual property, including the uncertainty of obtaining patents, the effectiveness of the patents or other intellectual property protections and ability to enforce them against third parties, the uncertainty regarding patent coverages, the possibility of infringing a third party’s patents or other intellectual property rights, and licensing risks; government contracting risks, including the appropriations process and funding priorities, potential bureaucratic delays in awarding contracts, process errors, politics or other pressures, and the risk that government tenders and contracts may be subject to cancellation, delay, restructuring or substantial delayed payments; the risk that delays in orders or shipments under government tenders or the Company’s U.S. prescription business could cause significant quarter-to-quarter variations in the Company’s operating results and adversely affect its net revenues and gross profit; a governmental tender award indicates acceptance of the bidder’s price rather than an order or guarantee of the purchase of any minimum number of units, and as a result government ministries or other public sector customers may order and purchase fewer units than the full maximum tender amount or award; penalties and/or debarment for failure to satisfy tender awards; the Company’s reliance on its international partners and on the level of spending by country governments, global donors and other public health organizations in the global public sector; risks related to concentration of accounts receivable with our largest customers and the collection of those receivables; the economic and business environment and the impact of government pressures; risks involved in doing business on an international level, including currency risks, regulatory requirements, political risks, export restrictions and other trade barriers; the Company’s production capacity, efficiency and supply constraints and interruptions, including potential disruption of production at the Company’s and third party manufacturing facilities and/or of the Company’s ability to timely supply product due to labor unrest or strikes, labor shortages, raw material shortages, physical damage to the Company’s and third party facilities, COVID-19 (including the impact of COVID-19 on suppliers of key raw materials), product testing, transportation delays or regulatory actions; risks related to the costs and other effects of litigation, including product liability claims; the Company’s ability to identify, successfully negotiate and complete suitable acquisitions or other strategic initiatives; the Company’s ability to successfully integrate acquired businesses, technologies or products; and other risks detailed in the Company’s press releases, shareholder communications and Securities and Exchange Commission filings, including Company’s Annual Report on Form 10-K for the year ended September 30, 2020 and subsequent quarterly reports on Form 10-Q. This documents are available on the “SEC Filings” section of our website at www.verupharma.com/investors. All forward-looking statements are based on information available to us as of the date hereof, and Company does not assume any liability and does not intend to update any forward-looking statements, except as required by law.
Oncology biopharmaceutical company
Focus on prostate cancer and breast cancer

Veru Drug Pipeline

- **Prostate Cancer**
  - Sabizabulin 32mg
  - VERU-100

- **Breast Cancer**
  - Enobosarm
  - Sabizabulin 32mg

- **COVID-19**
  - Sabizabulin 9mg

- **BPH**
  - TADFIN™ PDUFA – December 2021

- Late-stage clinical pipeline focused on prostate cancer & breast cancer
- 6 pivotal and pivotal-enabling clinical studies planned to commence in calendar year 2021

Veru Financials

- **UREV Women’s Health Division**
  - FC2 Female Condom (internal condom)
    - FC2 FY 2020 Net Revenues: $40.6 mm
    - FC2 FYTD 2021 Net Revenues: $44.8 mm
    - Sexual Health Business FYTD 2021 Operating Income: $32.8 mm
    - FC2 Q3 FY 2021 Net Revenues: $17.7 mm

- **Veru**
  - FY 2020 Net Revenues: $42.6 mm
  - FYTD 2021 Net Revenues: $45.6 mm
  - FYTD 2021 Gross Profit: $35.6 mm
  - Q3 FY 2021 Net Revenues: $17.7 mm
  - Q3 FY 2021 Gross Profit: $13.9 mm

- Cash: $123.2 mm
- Receivables: $8.3 mm
  (as of June 30, 2021)
<table>
<thead>
<tr>
<th>Program</th>
<th>Mechanism</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prostate Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sabizabulin</td>
<td>Oral cytoskeleton disruptor and androgen receptor transport disruptor</td>
<td>Metastatic castration and AR targeting agent resistant prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td>Phase 3 VERACITY: 245 Patients - Enrolling</td>
</tr>
<tr>
<td>VERU-100</td>
<td>Gonadotropin-releasing hormone antagonist 3-month subcutaneous depot injection</td>
<td>Hormone sensitive advanced prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td>Phase 2: 35 Patients - Enrolling</td>
</tr>
<tr>
<td><strong>Breast Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enobosarm</td>
<td>Selective androgen receptor targeted agonist</td>
<td>AR+ER+HER2 - metastatic breast cancer (3rd line metastatic)</td>
<td></td>
<td></td>
<td></td>
<td>Phase 3 ARTEST: Planned Q3 2021 - 210 Patients</td>
</tr>
<tr>
<td>Enobosarm + abemaciclib combination</td>
<td>Selective androgen receptor targeted agonist + CDK4/6 inhibitor</td>
<td>AR+ER+HER2 - metastatic breast cancer (2nd line metastatic)</td>
<td></td>
<td></td>
<td></td>
<td>Phase 2b: Planned Q4 2021 - 186 Patients</td>
</tr>
<tr>
<td>Sabizabulin</td>
<td>Oral cytoskeleton disruptor</td>
<td>Metastatic triple negative breast cancer</td>
<td></td>
<td></td>
<td></td>
<td>Phase 2b: Planned Q3 2021 - 216 Patients</td>
</tr>
<tr>
<td><strong>Virology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sabizabulin</td>
<td>Oral cytoskeleton disruptor</td>
<td>Hospitalized COVID-19 patients at high risk for ARDS</td>
<td></td>
<td></td>
<td></td>
<td>Phase 3: 300 Patients - Enrolling</td>
</tr>
</tbody>
</table>

1 Certain information herein represents objectives of the Company. Whether these objectives will be met as anticipated or at all depends on a variety of factors outside of the Company’s control.
# Prostate Cancer – Novel Medicines

<table>
<thead>
<tr>
<th>Program</th>
<th>Mechanism</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sabizabulin</td>
<td>Oral cytoskeleton disruptor and androgen receptor transport disruptor</td>
<td>Metastatic castration and AR targeting agent resistant prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td>Phase 3 VERACITY: 245 Patients</td>
</tr>
<tr>
<td>VERU-100</td>
<td>GnRH antagonist 3-month subcutaneous depot injection</td>
<td>Hormone sensitive advanced prostate cancer</td>
<td></td>
<td></td>
<td></td>
<td>Phase 2: 35 Patients</td>
</tr>
</tbody>
</table>
Sabizabulin is an oral agent that targets and disrupts the cytoskeleton

**AR independent**
Targets cytoskeleton to crosslink and inhibit microtubule assembly

- Targets the “colchicine binding site” to crosslink α and β subunits to inhibit microtubule polymerization (low nM concentration)
- Not a substrate for multidrug resistance proteins (P-gp, MRPs, and BCRP)
- Favorable toxicity profile no neurotoxicity and no neutropenia or myelosuppression
- Demonstrated activity against taxane, vinca alkaloid, doxorubicin, enzalutamide, and abiraterone resistant prostate cancers
- Has broad activity against other tumor types as well: Triple negative breast cancer (taxane resistant)\(^7\), Cervical cancer (taxane resistant)\(^8\), Lung cancer (taxane resistant)\(^9\), Ovarian cancer (taxane resistant)\(^10\), Uterine cancer\(^11\), Pancreatic cancer\(^12\), Melanoma\(^13\), Human promyelocytic leukemia (vincristine resistant)\(^14\)

**AR directed**
Disrupts androgen receptor transport

- AR binding to DNA and dimerization
- Translocation of dimerized AR into nucleus by dynein motor proteins moving along microtubule tracks
- Sabizabulin AR transport disruptor

---

4. 28 day rat and dog toxicity studies on file at Veru, Inc.  
10. Data on file Veru, Inc. 2020  
11. Data on file Veru, Inc. 2020  
DNA repair alterations (BRCA1 and BRCA2)

Metastatic castration and ARTA resistant prostate cancer

Current indication

10%

DNA repair alterations (BRCA1 and BRCA2)

Parp inhibitor Olaparib

Chemotherapy

Androgen Receptor Targeting Agent (ARTA)
- 15-25% of men have no response
- 75-85% of men progress in 9-15 months

Need for new safe and effective treatment alternatives with a distinct mechanism of action (non-AR dependent) and easy mode of administration remains an unmet need.

Sabizabulin clinical development
Phase 1b (expansion cohort) and Phase 2 clinical study design- ONGOING STUDY

Phase 1b- Dose escalation to evaluate safety of sabizabulin in men with metastatic castration resistant prostate cancer following at least one prior AR targeting agent therapy and up to one taxane

- 7 US sites – Johns Hopkins Kimmel Comprehensive Cancer Center (lead center)
- 39 patients enrolled
- Trial design - 2 part dosing schedule using standard 3+3 dose escalation strategy
  - Part 1- 7-day dose schedule – At each dose level, orally administered daily on Day 1-7 every 21 days (i.e. 7 days on, 14 days off)
  - Part 2- Expanded dose schedule – If 7-day dosing tolerated/safe, patients increased frequency to Day 1-14 daily dosing every 21 days (i.e. 14 days on, 7 days off). If 14-day dosing tolerated/safe, then advance to dosing daily with continuously until disease progression/toxicity

Phase 2- Evaluate safety and efficacy of sabizabulin RP2D 63mg PO q d in metastatic castration resistant prostate cancer and following at least one prior AR targeting agent therapy, but prior to IV chemotherapy

- 13 U.S. clinical centers
- 44 men enrolled
- Completed enrollment in September 2020
- Trial design
  - Open label
  - Recommended Phase 2 dose is 63mg/day
  - PK study to evaluate Phase 2 dosage versus Phase 3 dosage formulation
Phase 1b and 2 clinical studies
Baseline demographics

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Phase 1b</th>
<th>Phase 2</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>N</strong>=39</td>
<td></td>
<td>N=41</td>
</tr>
<tr>
<td><strong>Age, years</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median (range)</td>
<td>74 (61-92)</td>
<td>73 (57-86)</td>
</tr>
<tr>
<td><strong>Race/Ethnicity, n (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Caucasian</td>
<td>28 (72%)</td>
<td>31 (76%)</td>
</tr>
<tr>
<td>African American</td>
<td>8 (21%)</td>
<td>4 (10%)</td>
</tr>
<tr>
<td>Hispanic</td>
<td>3 (8%)</td>
<td>5 (12%)</td>
</tr>
<tr>
<td>Other</td>
<td>0</td>
<td>1 (2%)</td>
</tr>
<tr>
<td><strong>ECOG performance status, n (%)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0</td>
<td>21 (54%)</td>
<td>30 (73%)</td>
</tr>
<tr>
<td>1</td>
<td>16 (41%)</td>
<td>10 (24%)</td>
</tr>
<tr>
<td>2</td>
<td>2 (5%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td><strong>Metastatic disease location</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bone only</td>
<td>21 (55%)</td>
<td>24 (59%)</td>
</tr>
<tr>
<td>Lymph node only</td>
<td>6 (16%)</td>
<td>8 (20%)</td>
</tr>
<tr>
<td>Bone and lymph node</td>
<td>8 (21%)</td>
<td>7 (17%)</td>
</tr>
<tr>
<td>Visceral only</td>
<td>1 (3%)</td>
<td>0</td>
</tr>
<tr>
<td>Bone and visceral</td>
<td>1 (3%)</td>
<td>1 (2%)</td>
</tr>
<tr>
<td>Lymph node and visceral</td>
<td>0</td>
<td>1 (2%)</td>
</tr>
<tr>
<td><strong>Prior therapies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Abiraterone</td>
<td>14 (36%)</td>
<td>7 (17%)</td>
</tr>
<tr>
<td>Enzalutamide</td>
<td>8 (20%)</td>
<td>13 (32%)</td>
</tr>
<tr>
<td>Abiraterone and enzalutamide or apalutamide or proxalutamide</td>
<td>17 (44%)</td>
<td>14 (34%)</td>
</tr>
<tr>
<td>Apalutamide or proxalutamide</td>
<td>0</td>
<td>5 (12%)</td>
</tr>
<tr>
<td>Abiraterone and enzalutamide and apalutamide or proxalutamide</td>
<td>0</td>
<td>2 (5%)</td>
</tr>
<tr>
<td>Taxane</td>
<td>9 (23%)</td>
<td>3 (7%)</td>
</tr>
</tbody>
</table>
Sabizabulin clinical development
Safety - Phase 1b (expansion cohort) and Phase 2 clinical study

Most prevalent adverse events regardless of grade (>10% frequency) in patients that received 63 mg dose
N=54

<table>
<thead>
<tr>
<th>Adverse Event</th>
<th>All Grades regardless of relationship to study drug</th>
<th>Grade ≥3 regardless of relationship to study drug</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diarrhea</td>
<td>32 (59.3%)</td>
<td>4 (7.4%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>18 (33.3%)</td>
<td>3 (5.6%)</td>
</tr>
<tr>
<td>Nausea</td>
<td>17 (31.5%)</td>
<td>1 (1.9%)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>17 (31.5%)</td>
<td>0</td>
</tr>
<tr>
<td>Constipation</td>
<td>9 (16.7%)</td>
<td>0</td>
</tr>
<tr>
<td>ALT increased</td>
<td>10 (18.5%)</td>
<td>3 (5.6%)</td>
</tr>
<tr>
<td>AST increased</td>
<td>9 (16.7%)</td>
<td>2 (3.7%)</td>
</tr>
<tr>
<td>Back pain</td>
<td>8 (14.8%)</td>
<td>1 (1.9%)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>7 (13.0%)</td>
<td>1 (1.9%)</td>
</tr>
<tr>
<td>Abdominal pain</td>
<td>6 (11.1%)</td>
<td>0</td>
</tr>
<tr>
<td>Dysgeusia</td>
<td>6 (11.1%)</td>
<td>0</td>
</tr>
</tbody>
</table>

**At the recommended Phase 2 dose (RP2D) of 63 mg oral daily dose of sabizabulin**

- Sabizabulin was well tolerated with no reports of clinically relevant neutropenia or neurotoxicity
- Adverse events were mostly grade 1 and 2\(^1\)
- Safety profile appears similar as what is reported for an androgen receptor targeting agent
- Daily chronic drug administration is feasible and safe

**Diarrhea** was mostly (88%) grade 1 and 2 and medically manageable as only 1 patient discontinued clinical study because of this adverse event; expect this adverse event to be less in Phase 3 because of better oral bioavailability of Phase 3 dosage form and reduced exposure of GI tract to non-absorbed sabizabulin

\(^1\) Combined Phase 1b/2 efficacy data in men who received sabizabulin 63mg dose
Sabizabulin Phase 1b efficacy
PCWG3 criteria to evaluate efficacy after 12 weeks of treatment (4 cycles)

- 10 men reached at least four cycles of continuous dosing
  - Disease (4 Bone; 3 LN; and 3 LN+Bone)
  - Previous treatment- (5 Abi; 2 Enz; and 3 Abi+Enz)

- PSA responses
  - 6/10 had decrease in PSA
  - 4/10 had ≥ 30% decline in PSA
  - 2/10 had ≥ 50% decline in PSA

- Best objective tumor responses
  - 2 men had partial response (PR) (two additional objective responses occurred in subjects who did not reach 4 cycles)
  - 8 men had stable disease (SD)

- Median radiographic progression free survival
  - >12 months (range 6.0-28+ months)

- 2/10 men still on study as of August 2021

PSA waterfall plot

Ten men have reached ≥ 4 cycles of continuous dosing

Patent ID (dose)

Max PSA % decrease from baseline

Swimmers' plot

Ten men have reached ≥ 4 cycles of continuous dosing

Duration of Treatment

Months
Sabizabulin clinical development
Efficacy - Phase 1b (expansion cohort) and Phase 2 study

| In ITT population, all patients with measurable disease at baseline (n=29) | ORR (5PR +1CR observed): 20.7%\(^1\) |
| All evaluable patients that would qualify for Phase 3 (n=26) | ORR: 23.1%\(^1\) |
| In all patients\(^1\) that received ≥ 63 mg (n=55) | Median rPFS is estimated to be at least: 7.4 months (Actual median rPFS has not been reached in the Phase 2 as there are still 10 men on study\(^1\)) |

\(^1\)Combined Phase 1b/2 efficacy data in men who received sabizabulin 63mg dose as of February 2021 and excluded superscan disease where follow up of lesions is not possible
Patient: 104-001

- mCRPC with lymph node only disease
- Prior treatment included:
  - Sipuleucel-T
  - Enzalutamide
  - Abiraterone
- Efficacy
  - Still on study >28 months
  - -63% PSA from 21 day cycle initiation baseline
  - ORR= PR

March 08, 2019: Screening CT scan
RP LN 1.7cm X 1.5cm (measurable target lesion)

June 10, 2020: 15 months follow-up
RP LN 1.1cm X 1.0cm (-33% decrease to nonpathologic node)
Sabizabulin 1b/2 clinical development: Conclusions

Sabizabulin was well tolerated with evidence of significant and durable objective tumor responses

- At the recommended Phase 2 dose (RP2D) of 63mg oral daily dose of sabizabulin
  - Well tolerated with no reports of significant neutropenia or neurotoxicity.
  - Daily chronic drug administration is feasible and safe
  - Safety profile appears similar to that reported in package inserts for an androgen receptor targeting agent

- Evidence of antitumor activity was observed including PSA reductions, objective and durable tumor responses (CR+PR)

- May be potentially prescribed by both Urologists and Medical Oncologists
VERACITY - Randomized, Active-Controlled, Open label Phase 3 Study of Sabizabulin 32mg for the Treatment of Metastatic Castration-Resistant Prostate Cancer in Patients Whose Prior Treatment Failed with at Least One Androgen Receptor Targeting Agent – Lead PI – Robert Dreicer, MD

- Efficacy endpoints
  - Primary endpoints
    - Radiographic progression free survival (rPFS)
  - Secondary endpoints
    - Objective response rate
    - Duration of objective response
    - OS (interim analysis)
    - Time to IV chemo
    - Pain progression

- Assumptions
  - Median rPFS- 7.4 months for sabizabulin vs 3.7 months for alternative AR targeting agent*
  - Sample size - 245 men
    - 2:1 randomization
    - 155 events expected
    - $\alpha = 0.05$
    - 98% power
    - Drop out= 30%
    - 10 months recruitment time, 12 month follow up after last patient first dose

Randomized 2:1

**Based on Olaparib study\(^1\) and CARD study\(^2\) an alternative androgen receptor targeting agent is expected to have a median rPFS of 3.6-3.7 months in this similar population

\(^1\) de Bono J et al. NEJM April 28,2020 | \(^2\) de Wit R et al. NEJM 381:2506-18 2019
Quest for a better androgen deprivation therapy: VERU-100
Current commercial limitations

**LHRH agonist**

- Concerns over initial surge in T levels - “T surge”
- Escapes from castration T levels – periodic increases in T levels
- Up to 17% of men do not achieve castration
- Does not suppress FSH
- Black box warning for cardiovascular safety concerns

**GnRH antagonist**

- Painful subcutaneous injections: large loading and maintenance doses
  - Loading 6mL (2 X 3 mL)
  - Maintenance 4 mL
- No long acting depot available
- Must be given every month

---

New potential product to addresses limitations of current ADT
Long-acting 3 month depot GnRH antagonist may provide better alternative

**VERU-100 target product profile**\(^1,2\)

- Novel proprietary GnRH antagonist decapeptide delivery formulation
- 3 month slow release subQ depot with no loading dose
  - Better compliance
  - Injectable delivery formulation is consistent with current medical practice patient visit schedule and billing/reimbursement procedures (Medicare Part B)
- Better castration
  - Immediate testosterone suppression no initial testosterone surge
  - Suppression of testosterone to less than 20ng/dL
  - Fewer testosterone escapes (micro-increases in testosterone)
- No black box warning for cardiovascular adverse effects for this class of drugs

---

\(^1\)Developed in collaboration with Drug Delivery Experts, LLC (San Diego, California); \(^2\)Veru Inc. VERU-100 Target Prescribing Information

Phase 2 open label, dose finding VERU-100 GnRH antagonist long acting 3 month depot clinical trial actively enrolling approx. 35 men
## Breast Cancer – Novel Medicines

<table>
<thead>
<tr>
<th>Program</th>
<th>Mechanism</th>
<th>Indication</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Enobosarm</td>
<td>Selective androgen receptor targeted agonist</td>
<td>AR+ER+HER2-metastatic breast cancer (3rd line metastatic)</td>
<td></td>
<td></td>
<td></td>
<td>Phase 3 ARTEST: Planned Q3 2021 – 210 Patients</td>
</tr>
<tr>
<td>Enobosarm + abemaciclib</td>
<td>Selective androgen receptor targeted agonist + CDK4/6 inhibitor</td>
<td>AR+ER+HER2-metastatic breast cancer (2nd line metastatic)</td>
<td></td>
<td></td>
<td></td>
<td>Phase 2: Planned Q3 2021 – 166 Patients</td>
</tr>
<tr>
<td>Sabizabulin</td>
<td>Oral cytoskeleton disruptor</td>
<td>Metastatic triple negative breast cancer</td>
<td></td>
<td></td>
<td></td>
<td>Phase 2: Planned Q4 2021 – 216 Patients</td>
</tr>
</tbody>
</table>
Endocrine therapies that target estrogen receptor pathways are effective against ER+ breast cancer.

Resistance to endocrine and CDK4/6 inhibitor therapies eventually occurs which requires alternative treatment approaches including chemotherapy\textsuperscript{1, 2}

Current Endocrine Therapies

- Selective estrogen receptor modulators (tamoxifen and toremifene)
- ER antagonists and degraders (fulvestrant)
- Aromatase inhibitors (AI)
  - AROMASIN\textsuperscript{®} (exemestane) - steroidal AI
  - ARIMIDEX\textsuperscript{®} (anastrozole) and FEMARA \textsuperscript{®}(letrozole) - nonsteroidal AI
- CDK 4/6 inhibitors in combination with nonsteroidal AI or fulvestrant

\textsuperscript{1}Alluri et al., Breast Cancer Res 16:494, 2014 \textsuperscript{2}Basile D et al. Cancer Treatment Reviews 61:15-22, 2017
Androgen receptor is the most abundantly expressed sex hormone receptor in breast cancers with up to 95% of breast cancers.

- What is the androgen receptor’s function in breast tissue?
- Does activation of the androgen receptor stimulate or suppress breast cancer growth?
- In normal and cancerous breast tissue, androgens inhibit cellular proliferation.
- AR positivity is an independent predictor of beneficial breast cancer outcome.

- Historically, androgens have been used in breast cancer treatment with good efficacy, but their masculinizing effects, increase in hematocrit, and liver toxicity have prohibited their use as a viable treatment.
- The development of novel strategies to target and to activate AR, tumor suppressor, as a treatment for AR+ER+ breast cancer that have become resistant to drugs that target the ER is warranted.

Enobosarm, first-in-class, novel oral selective AR targeting agonist for the treatment for AR+ER+ metastatic breast cancer

- **Enobosarm is a non-steroidal, selective androgen receptor agonist**¹,²
  - Once-a-day oral daily dosing
  - Selectivity to activate the androgen receptor with no cross-reactivity to other steroidal hormone receptors
  - Not a substrate for aromatase, thus cannot be aromatized to estrogen
  - Builds and heals bone-potential to treat antiestrogen-induced osteoporosis and prevent skeletal related events³,⁴,⁵
  - Anabolic on muscle to improve muscle mass and physical function²,⁶
  - Selective tissue activities translate to a favorable side-effect profile
    - Non-masculinizing (no unwanted hair growth or acne)
    - No liver toxicity
    - No changes in hematocrit

- **Enobosarm suppresses AR+ER+ breast cancer in cell and patient-derived xenograft models of endocrine sensitive and resistant disease⁷**

---

1. Narayanan R et al. Mol Cell Endocrinol 2017
7. Hickey et al., Nature Medicine

Enobosarm has been evaluated in 25 clinical trials comprising 2,091 subjects (348 subjects dosed at > 9mg) which includes:

- 6 Phase 2 studies in breast cancer (5) or breast disease (1)
- 12 Phase 1 studies for NDA label completed
Phase 2 clinical trial (G200802) design
Targeting AR+ER+ metastatic breast cancer in a heavily pretreated population

Trial design

- Open label, multicenter, multinational, randomized parallel design Phase 2 study to assess the efficacy and safety of enobosarm 9 mg or 18 mg oral daily dose in postmenopausal subjects with AR+ER+ metastatic breast cancer

- Efficacy primary endpoint: To assess the clinical benefit rate (CBR) (CR + PR + SD) in subjects with AR+ breast cancer treated at 6 months (by RECIST 1.1)

Patient population - 136 women enrolled

- ER+ metastatic or locally recurrent breast cancer not amenable to surgery
  - AR status was assessed centrally (>10%) and AR+ patients were included in the evaluable patients
  - Patients that were AR negative, not determined or uninformative were not in the evaluable population

- Previously responded to adjuvant endocrine Tx for ≥3 years, or most recent endocrine Tx for metastatic disease ≥ 6 months

---

### Phase 2 clinical trial (G200802)
#### Patient baseline demographics

<table>
<thead>
<tr>
<th>Demographics</th>
<th>9 mg cohort</th>
<th>18 mg cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (median), years (range)</td>
<td>60.5 (35-83)</td>
<td>62.5 (42-81)</td>
</tr>
<tr>
<td>Caucasian (%)</td>
<td>98.0</td>
<td>94.2</td>
</tr>
<tr>
<td>Initial presentation of Stage IV metastatic breast cancer</td>
<td>12%</td>
<td>26.9%</td>
</tr>
<tr>
<td>Median months since initial diagnosis (range)</td>
<td>110.0 (19-435)</td>
<td>86.0 (15-323)</td>
</tr>
<tr>
<td>Median months since metastatic diagnosis (range)</td>
<td>34.3 (1-167)</td>
<td>27.4 (1-225)</td>
</tr>
<tr>
<td>Source of tissue AR primary/metastatic (%)</td>
<td>52/44</td>
<td>57.7/40.4</td>
</tr>
<tr>
<td>Median % of cells staining AR+ (range)</td>
<td>53.4 (11-96)</td>
<td>51.4 (14-98)</td>
</tr>
<tr>
<td>AR status confirmed centrally (%)</td>
<td>94.0</td>
<td>86.5</td>
</tr>
<tr>
<td>Bone only non-measurable (%)</td>
<td>38.0</td>
<td>32.7</td>
</tr>
<tr>
<td>Prior chemotherapy (%)</td>
<td>90.0</td>
<td>92.3</td>
</tr>
<tr>
<td>Median prior lines of endocrine therapy (range)</td>
<td>3.2 (1-7)</td>
<td>3.2 (1-7)</td>
</tr>
</tbody>
</table>
Enobosarm was well tolerated. Majority of events were Grade 1 and 2.

<table>
<thead>
<tr>
<th></th>
<th>9 mg N=75</th>
<th>18 mg N=61</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients with any SAEs</td>
<td>8 (10.7%)</td>
<td>10 (16.4%)</td>
</tr>
<tr>
<td>Grade 3 Drug Related Adverse Events</td>
<td>5</td>
<td>9</td>
</tr>
<tr>
<td>Grade 4 Drug Related Adverse Events</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Patients with Treatment-Emergent Adverse Events Leading to Death</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Grade 3 and 4 Drug Related Adverse Events</th>
<th>9 mg N=75</th>
<th>18 mg N=61</th>
</tr>
</thead>
<tbody>
<tr>
<td>Increased alanine aminotransferase</td>
<td>1 (1.3%)</td>
<td>2 (3.3%)</td>
</tr>
<tr>
<td>Increased aspartate aminotransferase</td>
<td>2 (2.7%)</td>
<td></td>
</tr>
<tr>
<td>Hypercalcemia</td>
<td>2 (2.6%)</td>
<td>2 (3.3%)</td>
</tr>
<tr>
<td>Headache</td>
<td>1 (1.3%)</td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>Anemia</td>
<td>1 (1.3%)</td>
<td></td>
</tr>
<tr>
<td>Dry mouth</td>
<td></td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>Decreased white blood cell count</td>
<td></td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td></td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>1 (1.3%)</td>
<td>2 (3.3%)</td>
</tr>
<tr>
<td>Tumor flare</td>
<td></td>
<td>2 (3.3%)</td>
</tr>
<tr>
<td>Agitation</td>
<td></td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>Lymphadenopathy</td>
<td></td>
<td>1 (1.6%)</td>
</tr>
<tr>
<td>Acute kidney injury</td>
<td></td>
<td>1 (1.6%)</td>
</tr>
</tbody>
</table>

Primary endpoint: CBR at 24 weeks

<table>
<thead>
<tr>
<th></th>
<th>9mg cohort</th>
<th>18mg cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of evaluable patients</td>
<td>50</td>
<td>52</td>
</tr>
<tr>
<td>Primary endpoint: CBR at 24 weeks</td>
<td>32% (95% CI: 19.5%;46.7%)</td>
<td>29% (95% CI: 17.1%;43.1%)</td>
</tr>
</tbody>
</table>
Phase 2 clinical trial (G200802) - AR is required for an objective tumor response

Best overall % target lesion reduction – Enobosarm 9 and 18 mg cohorts combined
### Post-hoc AR expression subset analysis:

- Subset of ITT with known AR status and have measurable disease (n=84)
- Combined both the 9mg and 18 mg cohorts to increase power of analysis

<table>
<thead>
<tr>
<th>% AR staining</th>
<th>% of patients (n)</th>
<th>CBR at 24 wks*</th>
<th>Best ORR**</th>
<th>Median rPFS***</th>
</tr>
</thead>
<tbody>
<tr>
<td>≥ 40%</td>
<td>56% (47)</td>
<td>52%</td>
<td>34%</td>
<td>5.47 months</td>
</tr>
<tr>
<td>&lt; 40%</td>
<td>44% (37)</td>
<td>14%</td>
<td>2.7%</td>
<td>2.70 months</td>
</tr>
</tbody>
</table>

*p<0.0004; **p<0.0003; ***p<0.001
Phase 2 clinical trial (G200802)- Conclusions
AR targeted therapy shows efficacy and safety in AR+ER+ metastatic breast cancer

• Enobosarm AR targeted treatment demonstrated clinical benefit with objective tumor responses in women with heavily pretreated estrogen blocking agent resistant AR+ ER+ HER2- metastatic breast cancer

• The presence of AR and expression of AR ≥ 40% enriched for subjects most likely to respond to enobosarm treatment

• Quality of life measurements demonstrated overall improvement including mobility, anxiety/depression and pain

• Enobosarm appears safe and well tolerated without masculinizing effects, increase in hematocrit, or liver toxicity

• The 9 mg dose selected for Phase 3 clinical study
  • 9 mg cohort had similar tumor responses with a slightly better toxicity profile than the 18 mg dose cohort

• Enobosarm represents a new class of endocrine therapy that targets and activates the AR, tumor suppressor, in AR+ ER+ HER2- metastatic breast cancer
NCCN 2020 guidelines: CDK 4/6 inhibitors are standard of care for treatment of ER+HER2- metastatic breast cancer

If disease progression on CDK4/6 inhibitor treatment, there are limited data to support additional line of treatment with another CDK 4/6 inhibitor containing regimen

First-Line Metastatic
- Nonsteroidal aromatase inhibitor + CKD4/6 inhibitor
- Fulvestrant + CDK 4/6 inhibitor

Second-Line Metastatic
- Fulvestrant + CDK 4/6; if CDK4/6 inhibitor was not previously used
- Enobosarm + Abemaciclib, CDK4/6 inhibitor

Third-Line Metastatic
- Enobosarm monotherapy
Phase 3 registration, open label, randomized ARTEST clinical trial (V3002401)(NCT#04869943)- 3rd line metastatic setting - anticipated start Q3 2021

**ARTEST Indication**
Treatment of AR+ER+HER2- metastatic breast cancer in subjects who have failed a nonsteroidal aromatase inhibitor, fulvestrant, and CDK4/6 inhibitor therapy (3rd line metastatic setting)

**ARTEST Clinical Trial Design**
Phase 3 open label, multicenter, multinational, randomized, active control pivotal study evaluating the efficacy and safety of enobosarm 9mg oral daily dose versus active control (exemestane ± everolimus or a SERM) in metastatic AR+ ER+ HER2- breast cancer

**ARTEST Patient Population**
- AR+ ER+ HER2-metastatic or recurrent locally advanced breast cancer, not amenable to curative treatment by surgery or radiotherapy, with objective evidence of disease progression
- Must have had received a nonsteroidal AI inhibitor, fulvestrant, and CDK 4/6 inhibitor for metastatic disease
  - Previously responded to hormone Tx for metastatic disease ≥ 6 months
  - No prior chemotherapy for the treatment of metastatic breast cancer
  - Centrally confirmed ≥ 40% AR nuclei staining from breast cancer sample

**ARTEST Efficacy Endpoints**
- **Primary endpoint:**
  - Median radiographic progression free survival (rPFS)
- **Secondary endpoints:**
  - Overall response rate (CR+PR)
  - Duration of response
  - Overall survival
  - Change in Short Physical Performance Battery (SPPB)
  - Change in European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-QLQ)

**ARTEST Sample Size Assumptions**
- Total sample size: 210
- \( \alpha = 0.05 \)
- 99% power
- 20% drop out rate
- 169 events
- Active control group (exemestane ± everolimus or a SERM): estimated median rPFS = 3 months\(^1\)\(^-\)\(^3\)
- Enobosarm arm: estimated median rPFS=6 months

Phase 3 Pivotal AR+ER+HER2-Metastatic Breast Cancer

3rd line metastatic setting
Failed nonsteroidal AI, fulvestrant, and CDK 4/6 inhibitor therapies
No prior chemotherapy
N=210

Recruitment: 10 months

Screening
Centrally confirmed ≥ 40% AR nuclei staining Parallel companion diagnostic development

Randomized 1:1

Enobosarm 9 mg

Active Control (Exemestane ± everolimus or SERM)

\(^1\)Yeruva, S et al. npj Breast Cancer 4: 1, 2018
\(^2\) Cook , M et al. The Oncologist 26:101,2021
\(^3\) Rozenblit M et al. Breast Cancer Research 23:14, 2021
Phase 2b (V2000701)- 2nd line metastatic setting
Open label, dose finding, efficacy and safety of CDK4/6 inhibitor (abemaciclib) + enobosarm combination versus active control estrogen blocking agent in AR+ER+HER2- metastatic breast cancer

Anticipated start date is calendar Q4 2021

Palbociclib resistance
Failed first line metastatic Tx

- Failed Nonsteroidal AI + Palbo or Fulvestrant + Palbo
- Centrally confirmed AR nuclei staining

Open label safety study to determine the safety of enobosarm in combination with abemaciclib

Stage 1
N=up to 6

Stage 2
2:1 rando n = 180

Combination
- Abemaciclib, CDK 4/6 inhibitor + Enobosarm

Active control
- Alternative estrogen blocking agent

Alternative estrogen blocking agent= Fulvestrant ➢ nonsteroidal AI or nonsteroidal AI ➢ fulvestrant

• Primary endpoint:
  • Median radiographic progression free survival (rPFS)

• Secondary endpoints:
  • Overall response rate (CR+PR)
  • Change in Short Physical Performance Battery (SPPB)
  • DEXA- body composition muscle and bone

Alternative estrogen blocking agent

CDK 4/6 inhibitor + Enobosarm

Palbociclib resistance
Failed nonsteroidal AI + Palbo or nonsteroidal AI + Fulvestrant

CDK 4/6 inhibitor + Enobosarm
Sabazibulin 9 mg

For the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome
Coronavirus is not going away!

**Situation by WHO Region**

- **Americas**
  - 77,688,636 confirmed
- **Europe**
  - 60,566,865 confirmed
- **South-East Asia**
  - 38,711,821 confirmed
- **Eastern Mediterranean**
  - 12,804,451 confirmed
- **Africa**
  - 5,023,726 confirmed
- **Western Pacific**
  - 4,669,948 confirmed

Source: World Health Organization

Data may be incomplete for the current day or week.
Sabizabulin: Phase 2 clinical trial design for COVID-19
Dual antiviral and anti-inflammatory action

Double-Blind, Placebo-Controlled, Phase 2 Study of Sabizabulin for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Patients at High Risk for Acute Respiratory Distress Syndrome (ARDS)¹

Trial design

- Approximately 40 subjects were randomized 1:1 (20 18mg sabazibulin and 20 Placebo groups)
- Hospitalized subjects with COVID-19 infection symptoms for less than 8 days and who are at high risk for ARDS were enrolled
- Subjects received study drug for up to 21 days
- The primary efficacy endpoint of the study was the proportion of patients that are alive and without respiratory failure at Day 29
- Most important secondary endpoints were all-cause mortality (death), days in ICU, and days on mechanical ventilation
- Enrollment completed December 2020

Patient demographics

<table>
<thead>
<tr>
<th></th>
<th>Sabizabulin</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of patients</td>
<td>19</td>
<td>20</td>
</tr>
<tr>
<td>Mean age (±SD)</td>
<td>59.3 (11.4)</td>
<td>57.8 (13.3)</td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Males (%)</td>
<td>10 (53%)</td>
<td>17 (85%)</td>
</tr>
<tr>
<td>Females (%)</td>
<td>9 (47%)</td>
<td>3 (15%)</td>
</tr>
<tr>
<td>Mean WHO Score at baseline (±SD)</td>
<td>4.47 (0.61)</td>
<td>4.7 (0.57)</td>
</tr>
<tr>
<td>Standard of care treatment use on study</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Remdesivir (%)</td>
<td>9 (47%)</td>
<td>15 (75%)</td>
</tr>
<tr>
<td>Dexamethasone (%)</td>
<td>13 (68%)</td>
<td>15 (75%)</td>
</tr>
<tr>
<td>No dexamethasone or remdesivir (%)</td>
<td>4 (21%)</td>
<td>2 (10%)</td>
</tr>
</tbody>
</table>

¹ Veru Inc, Clinical Trial Protocol, VERU-111 SARS-CoV-2 (May 2020)
# Phase 2 clinical trial of sabizabulin 18 mg

## Endpoints

<table>
<thead>
<tr>
<th>Primary Endpoint</th>
<th>Placebo</th>
<th>Sabizabulin</th>
<th>Relative Reduction</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Treatment failures, i.e. death or respiratory failure at Day 29 (MITT)</td>
<td>6/20 (30%)</td>
<td>1/18 (5.6%)</td>
<td>81%</td>
<td>p=0.05</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Secondary Endpoints</th>
<th>Placebo</th>
<th>Sabizabulin</th>
<th>Relative Reduction</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deaths (ITT)</td>
<td>6/20 (30%)</td>
<td>1/19 (5.3%)</td>
<td>82%</td>
<td>p=0.04</td>
</tr>
<tr>
<td>Treatment failures, i.e. death or respiratory failure at Day 29 in &gt;60 years of age</td>
<td>4/8 (50%)</td>
<td>1/11 (9%)</td>
<td>82%</td>
<td>p=0.05</td>
</tr>
<tr>
<td>Treatment failures, i.e. death or respiratory failure at Day 15 in patients with a WHO Score of Disease Severity ≥5 at baseline</td>
<td>7/13 (54%)</td>
<td>1/9 (11%)</td>
<td>80%</td>
<td>p=0.04</td>
</tr>
<tr>
<td>Mean days in ICU +/- SE</td>
<td>9.55±11.54 (n=20)</td>
<td>3.00±7.16 (n=18)</td>
<td>69%</td>
<td>p=0.04</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Endpoints – patients that received standard of care (remdesivir and/or dexamethasone)</th>
<th>Placebo</th>
<th>Sabizabulin</th>
<th>Relative Reduction</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Days in ICU</td>
<td>8.83±13.07 (n=18)</td>
<td>1.43±3.96 (n=14)</td>
<td>84%</td>
<td>p=0.02</td>
</tr>
<tr>
<td>Days on mechanical ventilation</td>
<td>6.00±10.57 (n=18)</td>
<td>0 (n=14)</td>
<td>100%</td>
<td>p=0.04</td>
</tr>
</tbody>
</table>
Safety outcomes for Sabizabulin 18mg from Phase 2 clinical trial

Any adverse event that occurred in ≥ 2 patients on study

<table>
<thead>
<tr>
<th>Preferred Term</th>
<th>Sabizabulin 18 mg (n=19) N (%)/ events</th>
<th>Placebo (n=20) N (%)/events</th>
</tr>
</thead>
<tbody>
<tr>
<td>Any</td>
<td>10 (52.6)/27</td>
<td>11 (55.0)/41</td>
</tr>
<tr>
<td>Constipation</td>
<td>2 (10.5)/2</td>
<td>2 (10.0)/2</td>
</tr>
<tr>
<td>Septic shock</td>
<td>1 (5.3)/1</td>
<td>2 (10.0)/2</td>
</tr>
<tr>
<td>Alanine aminotransferase increased</td>
<td>1 (5.3)/1</td>
<td>2 (10.0)/2</td>
</tr>
<tr>
<td>Aspartate aminotransferase increased</td>
<td>2 (10.5)/2</td>
<td>1 (5.0)/1</td>
</tr>
<tr>
<td>Acute kidney injury</td>
<td>0</td>
<td>2 (10.0)/2</td>
</tr>
<tr>
<td>Pneumomediastinum</td>
<td>0</td>
<td>2 (10.0)/2</td>
</tr>
<tr>
<td>Pneumothorax</td>
<td>1 (5.3)/1</td>
<td>3 (15.0)/3</td>
</tr>
<tr>
<td>Respiratory failure</td>
<td>0</td>
<td>4 (20.0)/4</td>
</tr>
</tbody>
</table>

Safety

• There were no treatment related adverse events observed on the study
• There were no treatment related serious adverse events observed on the study
• There is no imbalance against sabizabulin in adverse events observed in the study
Double-Blind, Placebo-Controlled, Phase 3 Study of Sabizabulin for the Treatment of in Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome (V3011902)(NCT#04842747) – enrolling

- Trial size is N=300 with a 2:1 randomization
- Dosing: daily dosing up to 21-days or until discharge from hospital
- Treatment arms: Sabizabulin 9 mg Formulated Capsule vs. Placebo
  - All patients will be allowed standard of care on the study (Remdesivir/dexamethasone/convalescent plasma)
- Key inclusion criteria: high risk for ARDS, hospitalized, WHO Ordinal Scale for Disease Progression ≥4
- Primary endpoint: proportion of patients who die prior to Day 60 (mortality)
- Key secondary endpoints: Respiratory failure, days in ICU, days on mechanical ventilation, days in the hospital, and viral load
- Multinational clinical sites in United States, Brazil, Mexico, Argentina, and Colombia with aim to complete recruitment by year end

Statistical assumptions

- In the Phase 2, the sabizabulin treated group showed a 5.3 % mortality rate in patients with WHO disease severity score ≥4 at baseline compared to a 30% mortality rate in the Placebo group in the same patient population
- With significance level α=0.05, and a 2:1 ratio of enrollment into the sabizabulin and Placebo arms respectively, the sample size is adequate to achieve >99% power
TADFIN™ for BPH
Co-administration of CIALIS (tadalafil 5 mg) and PROSCAR (finasteride 5 mg) is currently approved for the initial treatment of symptoms of BPH for up to 26 weeks\(^1\)

- Drug-drug interaction and co-administration studies are completed for combination indication\(^2\)

Each component is approved for:

- CIALIS (tadalafil 5 mg) daily- symptoms of BPH and erectile dysfunction
- PROSCAR (finasteride 5 mg) - symptoms and signs of prostate enlargement to decrease prostate size, reduces risk of acute urinary retention and need for surgery and prevents growth
- PROPECIA (finasteride 1mg) daily- symptoms of male pattern hair loss

The solution: proprietary TADFIN\(^\text{TM}\) tablet formulation:
Increases convenience and compliance

BPH TREATMENT THAT PREVENTS BPH PROGRESSION & ALSO IMPROVES ERECTILE DYSFUNCTION
PDUFA date 12/2021

\(^1\) Cialis (tadalafil) FDA Package Insert  
TADFIN™, only BPH treatment that prevents progression of BPH and improves sexual function\(^1\)\(^2\)

- International, randomized, double-blind study in approximately 700 men
- 350 men treated with placebo + 5mg finasteride each day
- 345 men treated with 5mg tadalafil + 5mg finasteride each day

---

**ED symptom score\(^2\)**

**Men with baseline ED**

**Men without baseline ED**

---

Figure 2. Comparison of treatment results with regard to IIEF scores reported by Glina et al.\(^2\)


**Abbreviations:** IIEF, International Index of Erectile Function; LS, least squares.

TADFIN™, only BPH treatment that prevents progression of BPH and improves sexual function

Market potential

- BPH market is up to 25% of male population and estimated 1.1 billion males worldwide in 2018

- Target men who have BPH as a cause for symptoms
  - Other men who may benefit according to Eikelany O et al.

  - Suboptimal response to 5α reductase inhibitor (PROSCAR® or AVODART®) alone with prostate enlargement
  - Suboptimal response to an alpha blocker (tamsulosin) alone or in combination with 5α reductase inhibitor (JAYLN®)
  - Optimal response to 5α reductase inhibitor, but also has erectile dysfunction

Market Potential
US and global markets expected to be $200 million through telemedicine channels

---

UREV
Women’s Health Division
FC2® Female Condom (internal condom) business revenues are growing

Sold in U.S. and 149 other countries

Manufacturing plant with annual capacity of 100 million units

Public sector customers include UNFPA, USAID, Brazil, and South Africa

FC2 business profitable from FY 2006-present¹

FC2 Female Condom (internal condom) is the only FDA approved female use product to prevent pregnancy and transmission of sexually transmitted infections

Rapidly growing US prescription business for high margin revenues

Prescription business is growing via existing and anticipated new contracts with additional telemedicine and telepharmacy partners

¹For fiscal year 2006 through fiscal year 2016, profitability is based on Veru’s net income attributable to common stockholders. Beginning fiscal year 2017, the first fiscal year which includes the financial results of Aspen Park Pharmaceuticals, Inc., profitability is based on operating income from our commercial segment.
FC2 revenues

FC2 global public sector & FC2 US prescription revenues ($ mm)

US Prescription
Global Public Sector

FC2 Revenues
FY 2018: $15.9 mm
FY 2019: $30.9 mm
FY 2020: $40.6 mm
FYTD 2021: $44.8 mm

FC2 US Prescription 12-Pack Units Sold
FY 2018: 24,000
FY 2019: 159,000
FY 2020: 342,000
FYTD 2021: 413,000
## Financial highlights

### Veru: Results of Operations

<table>
<thead>
<tr>
<th>FY 2020 Net Revenues</th>
<th>$ 42.6 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3 FY 2021 Net Revenues</td>
<td>$ 17.7 mm</td>
</tr>
<tr>
<td>Q3 FY 2021 Gross Profit</td>
<td>$ 13.9 mm</td>
</tr>
<tr>
<td>Q3 FY 2021 Operating Loss</td>
<td>$ 2.9 mm</td>
</tr>
<tr>
<td>FYTD 2021 Net Revenues</td>
<td>$ 45.6 mm</td>
</tr>
<tr>
<td>FYTD 2021 Gross Profit</td>
<td>$ 35.6 mm</td>
</tr>
<tr>
<td>FYTD 2021 Operating Income</td>
<td>$ 14.8 mm</td>
</tr>
<tr>
<td>FYTD 2021 Adjusted Operating Loss&lt;sup&gt;1&lt;/sup&gt;</td>
<td>$ 3.6 mm</td>
</tr>
</tbody>
</table>

### Veru: Balance Sheet as of June 30, 2021

<table>
<thead>
<tr>
<th></th>
<th>$</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash</td>
<td>123.2 mm</td>
</tr>
<tr>
<td>Receivables</td>
<td>8.3 mm</td>
</tr>
<tr>
<td>PREBOOST Payment Due</td>
<td>5.0 mm&lt;sup&gt;3&lt;/sup&gt;</td>
</tr>
<tr>
<td>US/UK NOL carryforward</td>
<td>42.0/$61.3 mm</td>
</tr>
<tr>
<td>Common Shares Outstanding:</td>
<td>~ 79.9 mm</td>
</tr>
</tbody>
</table>

### UREV – Women’s Health: Results of Operations

| FC2 FY 2020 Net Revenues: | $ 40.6 mm |
| Q3 FY 2021 Net Revenues : | $ 17.7 mm |

---

1. Represents a non-GAAP financial measure calculated by subtracting $18.4 mm gain on PREBOOST sale from Operating Income, a GAAP measure.
2. An aggregate of 10.8 million stock options and stock appreciation rights are outstanding and are, or could potentially be, dilutive in excess of the 79.7 million common shares above.
3. PREBOOST sale was $15 million in cash and $2.5 million in receivables at 12 months and $2.5 million in receivables at 18 months.
4. Cash received from the public offering, net of underwriting discounts and commissions, was $108.1 million.
5. Veru issued 7,419,354 shares of common stock in the public offering.

Record revenue FYTD from sexual health business $45.6 million

PREBOOST sale for $20 million

Veru closes public offering of $115 million in February 2021<sup>4,5</sup>
## Milestones

<table>
<thead>
<tr>
<th>Program</th>
<th>Mechanism</th>
<th>Indication</th>
<th>2021</th>
<th>2022</th>
<th>2023</th>
<th>2024</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Prostate Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sabizabulin</td>
<td>Oral cytoskeleton disruptor and androgen receptor transport disruptor</td>
<td>Metastatic castration and AR targeting agent resistant prostate cancer</td>
<td>Phase 3 Initiation</td>
<td>Phase 3 Full enrollment</td>
<td>NDA</td>
<td>Launch</td>
</tr>
<tr>
<td>VERU-100</td>
<td>Gonadotropin-releasing hormone antagonist 3-month subcutaneous depot injection</td>
<td>Hormone sensitive advanced prostate cancer</td>
<td>Phase 2 Initiation</td>
<td>Phase 2 Full enrollment</td>
<td>Phase 3 Initiation</td>
<td>Phase 3 Full enrollment</td>
</tr>
<tr>
<td><strong>Breast Cancer</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Enobosarm</td>
<td>Selective androgen receptor targeted agonist</td>
<td>AR+ER+HER2- metastatic breast cancer (3rd line metastatic)</td>
<td>Phase 3 Initiation</td>
<td>Phase 3 Full enrollment</td>
<td>NDA</td>
<td>Launch</td>
</tr>
<tr>
<td>Enobosarm + abemaciclib combination</td>
<td>Selective androgen receptor targeted agonist + CDK4/6 inhibitor</td>
<td>AR+ER+HER2- metastatic breast cancer (2nd line metastatic)</td>
<td>Phase 2 Initiation</td>
<td>Phase 2 Full enrollment</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sabizabulin</td>
<td>Oral cytoskeleton disruptor</td>
<td>Metastatic triple negative breast cancer</td>
<td>Phase 2 Initiation</td>
<td>Phase 2 Full enrollment</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Virology</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sabizabulin</td>
<td>Oral cytoskeleton disruptor</td>
<td>Hospitalized COVID-19 patients at high risk for ARDS</td>
<td>Phase 3 Initiation</td>
<td>Phase 3 Full enrollment</td>
<td>EUA/NDA</td>
<td></td>
</tr>
</tbody>
</table>